Hepatitis C virus, referred to as hepatitis C, hepatitis C, a hepatitis C virus (HCV) infection caused by viral hepatitis, mainly through blood transfusion, acupuncture and drug abuse spread, according to a report by the WHO, the HCV infection rate is about 3%, an estimated 180 million people are infected with HCV, new cases every year about 35 thousand of patients with hepatitis C. Hepatitis C is a global epidemic and can lead to chronic inflammatory necrosis and fibrosis in the liver. Some patients can develop cirrhosis and even hepatocellular carcinoma (HCC). In the next 20 years, the mortality related to HCV infection (liver failure and death caused by hepatocellular carcinoma) will continue to increase, which will cause great harm to the health and life of patients. It has become a serious social and public health problem.
Drug use: one of common drugs, nucleoside drugs
At present, the main drugs are mainly Leigh Bhave Lin, A Silowe and ganciclovir. These drugs are usually combined with other drugs for treatment. The curative effect is remarkable, such as interferon combined with Leigh Bhave Lin. Leigh Bhave Lin has a strong blocking effect on HCV, and is one of the most commonly used drugs for the treatment of hepatitis C.
Interferon two, interferon alpha
The drug belongs to a protein class of antiviral drugs, mainly to make the human body natural immunity protein using recombinant DNA method, name Hui Furen, Luo interferone, interference and Bellerau, after a period of treatment, patients with chronic hepatitis C serum HCVRNA negative rate of up to 50%-80%, but after stopping about half of HCVRNA positive, and alpha interferon is effective in HCV replication and visible indicators of negative, improvement of liver function and liver lesions improved.
Common drug three, compound interferon
The main drug compound interferon injection of recombinant interferon alpha -2b and Peginterferon alfa-2b Injection, the injection of recombinant human interferon, interferon is combined by gene recombination technique of various subtypes of recombinant interferon and non natural interferon alpha interferon, than the original effect of anti HCV at least 5 times, adverse reactions are mild to moderate. In the treatment, 9 micrograms of subcutaneous injection, 3 times a week, and 6-12 months were 1 courses.
Existing new drugs:
Hepatitis C drug Sophie Bouvet + Dhaka oseltamivir combination therapy can effectively kill the hepatitis C virus, the current experimental proof, Sophie Bouvet joint Dhaka oseltamivir medication for hepatitis C is higher than 95%.
Sophie Bbu Vee (English Sofosbuvir, marketed as Sovaldi) is the development of Gilead's new drug for the treatment of chronic hepatitis C in December 2013 6, the U.S. Food and Drug Administration (FDA) approved in the United States, in January 2014 16 the European Medicines Agency (EMEA) approved in the eu. The drug has not yet been listed in China, and Chinese patients can only go to foreign hospitals.
The drug is the first drug that is safe and effective in the treatment of certain types of hepatitis C without the need for combined interferon. Clinical trials for 1 and 4 of hepatitis C, the drug combination of pegylated interferon and Leigh Bhave Lin's overall rate of sustained virological response (SVR) up to 90%; for the 2 type of hepatitis C, combined with Leigh Bhave Lin the drug SVR 89%-95%; in 3 hepatitis C, the drug SVR 61%-63% combined with ribavirin forest. It is worth mentioning that the cable clinical trial also contains some non boue hepatitis C patients with cirrhosis, the curative effect is significant.
Dhaka oseltamivir is a therapeutic regimen combined with Sophie Bouvet because has won approval from the European Union, we called the "EU plan."." The EU programme has a good effect on genes 1, 2, and 3.
